Dantari, a Thousand Oaks, CA-based clinical-stage biotechnology company, raised $47M in Series A funding.
The round was led by Westlake Village BioPartners with participation from Corner Ventures, Alexandria Venture Investments, and Caltech. The company also announced the appointment of Richard A. Markus, M.D., Ph.D., as president and chief executive officer (CEO), and its board of directors, chaired by Sean Harper, M.D., a co-founding managing director at Westlake.
The company intends to use the funds for the advancement of its differentiated antibody-drug conjugate (ADC) and chemotherapeutic platforms.
Led by CEO Richard A. Markus, Dantari is a clinical-stage biotechnology company developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-capacity Drug Conjugate) chemotherapeutic agents starting with DAN-222 and next-generation ADC therapeutics T-HDC technology originating from Caltech. Dantari’s HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR), and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options.
FinSMEs
08/12/2022